Tianeptine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tianeptine: From Depression (Unconfirmed Label Indication) to Migraine Disorder
One-Sentence Summary
Tianeptine is an antidepressant marketed in Singapore as an oral tablet, although the registered indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for migraine disorder, but this is a model prediction only, with 0 clinical trials and 0 publications supporting this specific indication. The best-supported repurposing direction is headache disorder (1 Phase 2 trial in progress, no results yet) and dysthymic disorder (indirect literature from depression studies).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration data (tianeptine is known as an antidepressant) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 96.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Other predicted indications reviewed:
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Migraine disorder | 96.91% | L5 | Hold |
| 2 | Migraine with brainstem aura | 96.36% | L5 | Hold |
| 3 | Dysthymic disorder | 95.76% | L4 | Research Question |
| 4 | Migraine with or without aura, susceptibility to | 92.79% | L5 | Hold |
| 5 | Headache disorder | 92.77% | L2 | Research Question |
| 6 | Atrophoderma vermiculata | 92.60% | L5 | Hold |
| 7 | Trigeminal autonomic cephalalgia | 91.75% | L5 | Hold |
| 8 | Neurotic disorder | 91.30% | L4 | Hold |
| 9 | Ulerythema ophryogenesis | 90.54% | L5 | Hold |
| 10 | Common cold | 90.16% | L5 | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, tianeptine is an atypical antidepressant with a modified tricyclic structure. The supplied literature describes it as increasing serotonin uptake in the brain (unlike most antidepressants), reducing the stress-related hypothalamic-pituitary-adrenal response, and reducing stress-induced dendritic atrophy.
For migraine, a plausible link is tianeptine's modulation of glutamatergic neurotransmission and its mu-opioid receptor agonism. This remains speculative, since no trials or publications were supplied for migraine. The opioid activity also raises concerns about medication-overuse headache and dependence in a headache population.
The other migraine-related predictions (brainstem aura, susceptibility phenotype, trigeminal autonomic cephalalgia) most likely score highly because of their closeness to "migraine disorder" in the knowledge graph rather than independent evidence. The dermatological predictions (atrophoderma vermiculata, ulerythema ophryogenesis) and the common cold have no plausible mechanistic link and likely reflect graph artifacts.
Dysthymic disorder is the most biologically coherent prediction, as it sits close to tianeptine's known use in depression. However, the evidence is indirect (see below).
Clinical Trial Evidence
No clinical trials are registered for the top-ranked indication, migraine disorder. The only trial supplied is for the related headache disorder prediction:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06012552 | Phase 2 | Recruiting | 140 | Randomized, double-blind, placebo-controlled trial of tianeptine for post-COVID-19 "brain fog" symptoms, with PET, biochemical, immunological and electrophysiological studies. Expected completion October 2027; no results yet. |
Note: the trial title and summary concern cognitive symptoms after COVID-19. The link to a headache indication is not clear from the supplied text, so its relevance to migraine should be confirmed.
Literature Evidence
No publications were supplied for migraine disorder. The following literature relates to dysthymic disorder and headache disorder (the latter with only indirect support):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3067116 | 1988 | RCT | Neuropsychobiology | Double-blind trial of tianeptine vs amitriptyline in 129 depressed alcoholic patients (major depression or dysthymia); both groups improved steadily |
| 2700774 | 1989 | RCT | Neuropsychobiology | Multicentre double-blind trial in 265 outpatients with dysthymic disorder and anxiety; tianeptine 37.5 mg/day vs amitriptyline 75 mg/day |
| 21527126 | 2011 | Meta-analysis | J Clin Psychiatry | Antidepressant efficacy in dysthymia as a class; does not establish tianeptine-specific efficacy |
| 7774514 | 1995 | Review | Drugs | Review of pharmacology, pharmacokinetics and efficacy in depression and coexisting anxiety and depression |
| 11463130 | 2001 | Review | CNS Drugs | Review of tianeptine in depressive disorders; novel serotonin uptake profile; indirect support only for headache |
| 1389026 | 1992 | Review | Br J Psychiatry Suppl | Overview of comparative trials against reference antidepressants (similar efficacy to amitriptyline) |
| 1407480 | 1992 | Cohort | Neuropsychobiology | Open study of 1,858 depressed patients in general practice; safety and efficacy at 37.5 mg/day |
| 1389025 | 1992 | Cohort | Br J Psychiatry Suppl | Long-term use in depressed patients after alcohol withdrawal |
| 2101783 | 1990 | Cohort | L'Encephale | One-year tolerability in 170 depressed patients |
| 2201514 | 1990 | Cohort | L'Encephale | One-year treatment results in a subgroup of a 1,231-patient long-term trial |
None of these is a dysthymia-specific tianeptine trial in a pure dysthymia population, so the evidence is drawn from the broader depression literature.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11182P | STABLON TABLET 12.5 mg | Tablet, sugar coated (oral) | Not stated in the registration data |
Manufacturer: Les Laboratoires Servier Industrie. Status: valid, single-ingredient product.
Safety Considerations
- Misuse and dependence: The literature supplied for the dysthymia prediction notes misuse and dependence liability reported with tianeptine. Its mu-opioid receptor agonism raises particular concern for medication-overuse headache and dependence if used in headache or migraine populations.
No warnings, contraindications, or drug interaction data were available in the data compiled for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (migraine disorder, 96.91%) rests on the model score alone, with no trials or publications. The best-supported directions are headache disorder (one ongoing Phase 2 trial of unclear headache relevance, no results) and dysthymic disorder (indirect evidence from depression studies, which could be pursued as a research question). The opioid-related dependence risk adds caution for any headache use.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- The registered indication text for SIN11182P
- Mechanism of action data (e.g., from DrugBank)
- Clarification of whether NCT06012552 actually evaluates a headache outcome, and its results when available
- Migraine-specific preclinical or clinical evidence, including an assessment of medication-overuse headache and dependence risk
- A dysthymia-specific tianeptine evidence review if that direction is pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.